Differential effects of methadone and buprenorphine on the response of D2/D3 dopamine receptors in adolescent mice

Drug and Alcohol Dependence

Volumn 132, Issue 3, 2013, Pages 420-426

  Barwatt, J William ^a   Hofford, Rebecca S ^a   Emery, Michael A ^a   Bates, M L Shawn ^a   Wellman, Paul J ^a   Eitan, Shoshana ^a  

^a TEXAS A AND M UNIVERSITY   (United States)

Author keywords

Addiction; Dependence; Drugs of abuse; Maintenance treatment; Opioid; Pain management

Indexed keywords

BUPRENORPHINE; DOPAMINE 2 RECEPTOR; DOPAMINE 3 RECEPTOR; METHADONE; QUINPIROLE; SODIUM CHLORIDE;

ADOLESCENCE; ARTICLE; CONTROLLED STUDY; DOPAMINE RELEASE; DOPAMINERGIC TRANSMISSION; DRUG ABUSE; DRUG RESPONSE; LOCOMOTION; MAINTENANCE THERAPY; MENTAL DISEASE; MENTAL HEALTH; MOUSE; NEUROCHEMISTRY; NONHUMAN; PRESYNAPTIC INHIBITION; PRIORITY JOURNAL; PROTEIN EXPRESSION; RISK ASSESSMENT; SIGNAL TRANSDUCTION; TEMPORAL ANALYSIS;

ANIMALIA; MUS;

ADDICTION; DEPENDENCE; DRUGS OF ABUSE; MAINTENANCE TREATMENT; OPIOID; PAIN MANAGEMENT;

AGE FACTORS; ANALGESICS, OPIOID; ANIMALS; BUPRENORPHINE; DOPAMINE AGONISTS; DOSE-RESPONSE RELATIONSHIP, DRUG; MALE; METHADONE; MICE; MICE, INBRED C57BL; MOTOR ACTIVITY; RECEPTORS, DOPAMINE D2; RECEPTORS, DOPAMINE D3;

EID: 84883561089     PISSN: 03768716     EISSN: 18790046     Source Type: Journal    
DOI: 10.1016/j.drugalcdep.2013.07.016     Document Type: Article

References (50)

1. Anghelescu D.L., Faughnan L.G., Hankins G.M., Ward D.A., Oakes L.L. Methadone use in children and young adults at a cancer center: a retrospective study. J. Opioid Manage. 2011, 7:353-361.
2. Arttamangkul S., Quillinan N., Low M.J., von Zastrow M., Pintar J., Williams J.T. Differential activation and trafficking of mu-opioid receptors in brain slices. Mol. Pharmacol. 2008, 74:972-979.
3. Ashby C.R., Paul M., Gardner E.L., Heidbreder C.A., Hagan J.J. Acute administration of the selective D3 receptor antagonist SB-277011A blocks the acquisition and expression of the conditioned place preference response to heroin in male rats. Synapse 2003, 48:154-156.
4. Bell J., Mutch C. Treatment retention in adolescent patients treated with methadone or buprenorphine for opioid dependence: a file review. Drug Alcohol Rev. 2006, 25:167-171.
5. Blum K., Noble E.P., Sheridan P.J., Finley O., Montgomery A., Ritchie T., Ozkaragoz T., Fitch R.J., Sadlack F., Sheffield D., et al. Association of the A1 allele of the D2 dopamine receptor gene with severe alcoholism. Alcohol 1991, 8:409-416.
6. De Vries T.J., Schoffelmeer A.N., Binnekade R., Vanderschuren L.J. Dopaminergic mechanisms mediating the incentive to seek cocaine and heroin following long-term withdrawal of iv drug self-administration. Psychopharmacology (Berl.) 1999, 143:254-260.
7. Dockstader C.L., Rubinstein M., Grandy D.K., Low M.J., van der Kooy D. The D2 receptor is critical in mediating opiate motivation only in opiate-dependent and withdrawn mice. Eur. J. Neurosci. 2001, 13:995-1001.
8. Druhan J.P., Walters C.L., Aston-Jones G. Behavioral activation induced by D2-like receptor stimulation during opiate withdrawal. J. Pharmacol. Exp. Ther. 2000, 294:531-538.
9. Elmer G.I., Pieper J.O., Rubinstein M., Low M.J., Grandy D.K., Wise R.A. Failure of intravenous morphine to serve as an effective instrumental reinforcer in dopamine D2 receptor knock-out mice. J. Neurosci. 2002, 22:RC224.
10. Fiellin D.A. Treatment of adolescent opioid dependence: no quick fix. JAMA 2008, 300:2057-2059.
11. Gershon A.A., Vishne T., Grunhaus L. Dopamine D2-like receptors and the antidepressant response. Biol. Psychiatry 2007, 61:145-153.
12. Halberda J.P., Middaugh L.D., Gard B.E., Jackson B.P. DAD1- and DAD2-like agonist effects on motor activity of C57 mice: differences compared to rats. Synapse 1997, 26:81-92.
13. Hillier W. Methadone Maintenance Treatment Program Standards and Clinical Guidelines 2011, College of Physicians and Surgeons of Ontario, Toronto, Ontario. fourth ed.
14. Hofford R.S., Wellman P.J., Eitan S. Morphine alters the locomotor responses to a D2/D3 dopamine receptor agonist differentially in adolescent and adult mice. J. Psychopharm. 2012, 26:1355-1365.
15. Johnston L.D., O'Malley P.M., Bachman J.G., Schulenberg J.E. Monitoring the future national survey results on drug use, 1975-2010: Volume I, Secondary school students 2011, The University of Michigan Institute for Social Research, Ann Arbor, MI.
16. Kalliokoski O., Jacobsen K.R., Hau J., Abelson K.S. Serum concentrations of buprenorphine after oral and parenteral administration in male mice. Vet. J. 2011, 187:251-254.
17. Kalvass J.C., Olson E.R., Cassidy M.P., Selley D.E., Pollack G.M. Pharmacokinetics and pharmacodynamics of seven opioids in p-glycoprotein-competent mice: assessment of unbound brain EC50,u and correlation of in vitro, preclinical, and clinical data. J. Pharmacol. Exp. Ther. 2007, 323:346-355.
18. Kleber H.D., Weiss R.D., Anton R.F., George T.P., Greenfield S.F., Kosten T.R., O'Brien C.P., Rounsaville B.J., Strain E.C., Ziedonis D.M., Hennessy G., Connery H.S. Practice Guideline for the Treatment of Patients With Substance Use Disorders 2006, American Psychiatric Association, Arlington, VA. second ed.
19. Leavitt S.B. Methadone Dosing & Safety in the Treatment of Opioid Addiction. AT Forum 2003, Clinco Communications, Inc., Mundelein, IL.
20. Lee J.M., DeLeon-Jones F., Fields J.Z., Ritzmann R.F. Cyclo (leu-gly) attenuates the striatal dopaminergic supersensitivity induced by chronic morphine. Alcohol Drug Res. 1987, 7:1-10.
21. Leri F., Tremblay A., Sorge R.E., Stewart J. Methadone maintenance reduces heroin- and cocaine-induced relapse without affecting stress-induced relapse in a rodent model of poly-drug use. Neuropsychopharmacology 2004, 29:1312-1320.
22. LeVier D.G., Brown R.D., Musgrove D.L., Butterworth L.F., McCay J.A., White K.L., Fuchs B.A., Harris L.S., Munson A.E. The effect of methadone on the immune status of B6C3F1 mice. Fundam. Appl. Toxicol. 1995, 24:275-284.
23. Li S.M., Collins G.T., Paul N.M., Grundt P., Newman A.H., Xu M., Grandy D.K., Woods J.H., Katz J.L. Yawning and locomotor behavior induced by dopamine receptor agonists in mice and rats. Behav. Pharmacol. 2010, 21:171-181.
24. Li T., Hou Y., Yan C.X., Chen T., Zhao Y., Li S.B. Dopamine D3 receptor knock-out mice display deficits in locomotor sensitization after chronic morphine administration. Neurosci. Lett. 2010, 485:256-260.
25. Maldonado R., Saiardi A., Valverde O., Samad T.A., Roques B.P., Borrelli E. Absence of opiate rewarding effects in mice lacking dopamine D2 receptors. Nature 1997, 388:586-589.
26. Marsteller D.A., Gerald C.P.G., Kong R., Cajina M., Craig D.A., Swanson C.J. The MCH1 receptor antagonist SNAP 94847 induces sensitivity to dopamine D2/D3 receptor agonists in rats and mice. Eur. J. Pharmacol. 2009, 602:66-72.
27. Michel E., Anderson B.J., Zernikow B. Buprenorphine TTS for children-a review of the drug's clinical pharmacology. Paediatr. Anaesth. 2011, 21:280-290.
28. Middaugh L.D., Kapetanovic I.M., Sweeney D.J., Ingram D.K. Methadone in brain and its effects on locomotor activity of young and aged mice. Neurobiol. Aging 1983, 4:321-326.
29. Millan M.J., Seguin L., Gobert A., Cussac D., Brocco M. The role of dopamine D3 compared with D2 receptors in the control of locomotor activity: a combined behavioural and neurochemical analysis with novel, selective antagonists in rats. Psychopharmacology (Berl.) 2004, 174:341-357.
30. Mogenson G.J., Wu M. Effects of administration of dopamine D2 agonist quinpirole on exploratory locomotion. Brain Res. 1991, 551:216-220.
31. Moody D.E., Fang W.B., Morrison J., McCance-Katz E. Gender differences in pharmacokinetics of maintenance dosed buprenorphine. Drug Alcohol Depend. 2011, 118:479-483.
32. Narita M., Mizuo K., Mizoguchi H., Sakata M., Tseng L.F., Suzuki T. Molecular evidence for the functional role of dopamine D3 receptor in the morphine-induced rewarding effect and hyperlocomotion. J. Neurosci. 2003, 23:1006-1012.
33. Nemoda Z., Szekely A., Sasvari-Szekely M. Psychopathological aspects of dopaminergic gene polymorphisms in adolescence and young adulthood. Neurosci. Biobehav. Rev. 2011, 35:1665-1686.
34. Patel M.B., Patel C.N., Rajashekara V., Yoburn B.C. Opioid agonists differentially regulate μ-opioid receptors and trafficking proteins in vivo. Mol. Pharmacol. 2002, 62:1464-1470.
35. PATS The Partnership Attitude Tracking Study (PATS), Teens 2008 Report 2009, Partnership for a Drug-Free America, New York.
36. Piepponen T.P., Katajamäki J., Kivastik T., Zharkovsky A., Ahtee L. Behavioural and neurochemical sensitization of morphine-withdrawn rats to quinpirole. Pharmacol. Biochem. Behav. 1996, 54:787-792.
37. Reddy P.L., Veeranna, Thorat S.N., Bhargava H.N. Evidence for the behavioral supersensitivity of dopamine D2 receptors without receptor up-regulation in morphine-abstinent rats. Brain Res. 1993, 607:293-300.
38. SAMHSA The NSDUH Report: Trends in Nonmedical Use of Prescription Pain Relievers: 2002 to 2007. Substance Abuse and Mental Health Services Administration 2009, Office of Applied Studies, Rockville, MD.
39. Sanberg P.R., Zoloty S.A., Willis R., Ticarich C.D., Rhoads K., Nagy R.P., Mitchell S.G., Laforest A.R., Jenks J.A., Harkabus L.J., et al. Digiscan activity: automated measurement of thigmotactic and stereotypic behavior in rats. Pharmacol. Biochem. Behav. 1987, 27:569-572.
40. Seeman P. All roads to schizophrenia lead to dopamine supersensitivity and elevated dopamine D2(high) receptors. CNS Neurosci. Ther. 2011, 17:118-132.
41. Shannon H.E., Bemis K.G., Peters S.C. Potency and efficacy of dopamine agonists in mouse strains differing in dopamine cell and receptor number. Pharmacol. Biochem. Behav. 1991, 40:103-107.
42. Simkin D.R., Grenoble S. Pharmacotherapies for adolescent substance use disorders. Child Adolesc. Psychiatr. Clin. N. Am. 2010, 19:591-608.
43. Smith J.W., Fetsko L.A., Xu R., Wang Y. Dopamine D2L receptor knockout mice display deficits in positive and negative reinforcing properties of morphine and in avoidance learning. Neuroscience 2002, 113:755-765.
44. Spear L.P. The adolescent brain and age-related behavioral manifestations. Neurosci. Biobehav. Rev. 2000, 24:417-463.
45. Starke K., Gothert M., Kilbinger H. Modulation of neurotransmitter release by presynaptic autoreceptors. Physiol. Rev. 1989, 69:864-989.
46. Svestka J. Treatment of bipolar depression. Neuro. Endocrinol. Lett. 2005, 26(Suppl. 1):27-47.
47. Usiello A., Baik J.-H., Rouge-Pont F., Picetti R., Dierich A., LeMeur M., Piazza P.V., Borrelli E. Distinct functions of the two isoforms of dopamine D2 receptors. Nature 2000, 408:199-203.
48. Wang Y., Xu R., Sasaoka T., Tonegawa S., Kung M.P., Sankoorikal E.B. Dopamine D2 long receptor-deficient mice display alterations in striatum-dependent functions. J. Neurosci. 2000, 20:8305-8314.
49. Wellman P.J., Davis K.W., Clifford P.S., Rothman R.B., Blough B.E. Changes in feeding and locomotion induced by amphetamine analogs in rats. Drug Alcohol Depend. 2009, 100:234-239.
50. Zhang J., Ferguson S.S., Barak L.S., Bodduluri S.R., Laporte S.A., Law P.Y., Caron M.G. Role for G protein-coupled receptor kinase in agonist-specific regulation of mu-opioid receptor responsiveness. Proc. Natl. Acad. Sci. U.S.A. 1998, 95:7157-7162.